ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 225 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 1.47 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $117,539,000 | +20.1% | 3,418,861 | +0.8% | 0.10% | +17.1% |
| Q4 2016 | $97,834,000 | -3.8% | 3,392,171 | +6.1% | 0.08% | -4.7% |
| Q3 2016 | $101,699,000 | -2.1% | 3,197,082 | -0.1% | 0.09% | -2.3% |
| Q2 2016 | $103,923,000 | +37.8% | 3,201,615 | +18.7% | 0.09% | +35.4% |
| Q1 2016 | $75,439,000 | +30.1% | 2,698,066 | +65.9% | 0.06% | +32.7% |
| Q4 2015 | $57,976,000 | -45.9% | 1,626,247 | -49.8% | 0.05% | +2.1% |
| Q3 2015 | $107,116,000 | -15.3% | 3,239,074 | +7.2% | 0.05% | -53.8% |
| Q2 2015 | $126,499,000 | +37.9% | 3,020,512 | +7.3% | 0.10% | +38.7% |
| Q1 2015 | $91,713,000 | +8.9% | 2,814,149 | +6.1% | 0.08% | +4.2% |
| Q4 2014 | $84,245,000 | +30.2% | 2,653,382 | +1.5% | 0.07% | +22.0% |
| Q3 2014 | $64,706,000 | +118.2% | 2,613,343 | +99.1% | 0.06% | +118.5% |
| Q2 2014 | $29,654,000 | -0.9% | 1,312,725 | +6.7% | 0.03% | -3.6% |
| Q1 2014 | $29,921,000 | +28.3% | 1,229,809 | +31.8% | 0.03% | +27.3% |
| Q4 2013 | $23,315,000 | – | 932,993 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |